Regulation, and the interpretation of existing rules, of cannabis in all its forms is a recurring subject in France, and one that is set to continue following the Court of Justice of the European Union (CJEU)’s recent decision in the Kanavape case. Aside from changes relating to that, there are a number of other proposals relating to France’s medical cannabis regime. This report provides a detailed overview of all current and possible future regulation.
If you purchase a report that is updated in the next 60 days, we will send you the new report for free.
Reasons to buyThe CJEU’s recent ruling is likely to have deep consequences for Europe’s CBD industry, and while France has not released an interpretation yet, the government will have no choice but to adapt to the ruling. If you are interested in France’s regulatory framework for CBD and cannabis, then this report will provide you with everything you need to know, from processing and cultivation of hemp to the country’s medical and recreational regimes.
Table of contents1 Executive summary
2 Outlook
3 Hemp plant
4 Extracts as a finished product
5 Finished products containing CBD and extracts
6 Import and export requirements
7 Enforcement actions
8 Medical cannabis
9 Recreational cannabis
10 Relevant laws
11 Relevant bodies
MethodologyThe research is completely original and conducted by CBD-Intel’s multilingual legal analysis team using several sources, including online and offline resources and data, specialised legal software, interviews with key stakeholders and government officials, and via the collaboration with local lawyers and on-the-ground professionals.
Latest reportsRegulation, and the interpretation of existing rules, of cannabis in all its forms is a recurring subject in France, and one that is set to continue following the Court of Justice of the European Union (CJEU)’s recent decision in the Kanavape case. Aside from changes relating to that, there are a number of other proposals relating to France’s medical cannabis regime. This report provides a detailed overview of all current and possible future regulation.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.